Evidence map›Paper›PMID 18979152›Full record

SynthesisJournal of bone and mineral metabolism2008

Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls.

Siobhan O'Donnell, David Moher, Kelli Thomas, David A Hanley, Ann Cranney

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of bone and mineral metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 7 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 7 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Vitamin D supplementation for prevention of mortality in adults.The Cochrane database of systematic reviews · 2014
    Pooled it
  6. Pooled it
  7. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Siobhan O'DonnellClinical Epidemiology Program, Ottawa Health Research Institute, 1053 Carling Avenue, ASB 1-006, Ottawa, Ontario, Canada, K1Y 4E9. odonnell.sioban1@gmail.com
David Moher
Kelli Thomas
David A Hanley
Ann Cranney
Health Canada · CAOttawa Hospital · CAUniversity of Calgary · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our objective was to conduct a systematic review on the benefits and harms of calcitriol and alfacalcidol in the reduction of fracture and fall risk. Randomized controlled trials (RCTs) comparing these agents to placebo or calcium and reporting fracture and fall incidence were retrieved from MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. Two reviewers independently determined study eligibility, assessed trial quality, and extracted data. Twenty-three RCTs were included (2139 participants), and 16 trials had sufficient data for meta-analysis. Vertebral fractures were not significantly reduced based on the combined results of 13 trials; however, subgroup analyses demonstrated a significant reduction with alfacalcidol [odds ratio (OR) = 0.50, 95% confidence interval (CI), 0.25-0.98], but not with calcitriol. There was a significant reduction in nonvertebral fractures (six trials, OR = 0.51, 95% CI, 0.30-0.88), and falls (two trials, OR = 0.66, 95% CI, 0.44-0.98). There was an increased risk of hypercalcemia (OR = 3.63, 95% CI, 1.51-8.73) and a trend toward an increased risk of hypercalciuria. There is evidence to suggest that these agents may reduce the incidence of nonvertebral fractures and falls; however, their benefit on vertebral fracture reduction may depend on the type of active vitamin D. Hypercalcemia and hypercalciuria are potential side effects.

Indexed as

Fractures, BoneAccidental FallsBone Density Conservation AgentsCalcitriolCalciumHumansHydroxycholecalciferolsMEDLINEPlacebosRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomealfacalcidolBone Density Conservation AgentsCalcitriolCalciumHydroxycholecalciferolsPlacebos

Identifiers

PMID18979152
OpenAlexW2096149768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.